On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series of political decisions ...

Litigation Trend Analysis The December 23, 2025 decision in In re Outlook Therapeutics, Inc. Securities Litigation (D.N.J., ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Boston spent the past decade selling itself as the safest bet in science, a place where a doctorate was practically a ticket ...

A life-sciences job in Boston used to be a sure path to a high-paying career, but empty labs and unemployed grads now herald ...